A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors

IF 503.1 1区医学 Q1 ONCOLOGY

CA: A Cancer Journal for Clinicians Pub Date : 2025-01-10 DOI:10.3322/caac.21870

Chadi Hage Chehade MD, Georges Gebrael MD, Nicolas Sayegh MD, Zeynep Irem Ozay MD, Arshit Narang MBBS, Tony Crispino, Talia Golan MD, Jennifer K. Litton MD, Umang Swami MD, MS, Kathleen N. Moore MD, Neeraj Agarwal MD

{"title":"A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors","authors":"Chadi Hage Chehade MD, Georges Gebrael MD, Nicolas Sayegh MD, Zeynep Irem Ozay MD, Arshit Narang MBBS, Tony Crispino, Talia Golan MD, Jennifer K. Litton MD, Umang Swami MD, MS, Kathleen N. Moore MD, Neeraj Agarwal MD","doi":"10.3322/caac.21870","DOIUrl":null,"url":null,"abstract":"Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications. This review offers a comprehensive clinical overview of PARP inhibitor approvals, emphasizing their efficacy across different cancers based on landmark phase 3 clinical trials.","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"75 2","pages":"141-167"},"PeriodicalIF":503.1000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21870","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CA: A Cancer Journal for Clinicians","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.3322/caac.21870","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications. This review offers a comprehensive clinical overview of PARP inhibitor approvals, emphasizing their efficacy across different cancers based on landmark phase 3 clinical trials.

Abstract Image

查看原文本刊更多论文

聚二磷酸腺苷核糖聚合酶抑制剂在泛肿瘤中的作用综述

聚（腺苷二磷酸核糖）聚合酶（PARP）抑制剂，如奥拉帕尼、塔拉唑帕尼、鲁卡帕尼和尼拉帕尼，包括针对参与DNA修复的PARP蛋白的治疗类。具有同源重组修复缺陷的癌细胞，特别是BRCA突变，由于PARP抑制剂诱导的合成致死性，对这些药物表现出更高的敏感性。这些药物显著改善了各种恶性肿瘤的生存结果，最初在卵巢癌中获得监管批准，随后在不同适应症中用于乳腺癌、胰腺癌和前列腺癌。本综述提供了PARP抑制剂批准的全面临床概述，强调了基于具有里程碑意义的3期临床试验对不同癌症的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CA: A Cancer Journal for Clinicians 医学-肿瘤学

CiteScore

873.20

自引率

0.10%

发文量

审稿时长

1 months

期刊介绍： CA: A Cancer Journal for Clinicians" has been published by the American Cancer Society since 1950, making it one of the oldest peer-reviewed journals in oncology. It maintains the highest impact factor among all ISI-ranked journals. The journal effectively reaches a broad and diverse audience of health professionals, offering a unique platform to disseminate information on cancer prevention, early detection, various treatment modalities, palliative care, advocacy matters, quality-of-life topics, and more. As the premier journal of the American Cancer Society, it publishes mission-driven content that significantly influences patient care.